Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept (RC18) Phase IIb Trial in SLE
NCT02885610Phase 2Completed
- Sponsor
- RemeGen
- Start
- Dec 2015
- Primary completion
- Jun 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of telitacicept in systemic lupus erythematosus (SLE) (4 arms), sponsored by RemeGen. Primary endpoint: SLE Responder Index (SRI) Response Rate at 48 weeks. Started Dec 2015; status: completed.
02
Drugs
telitacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02885610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02885610.